Analysis of Metabonomics for Pleural Effusion

NCT05906823 | Completed

• 1 other identifier: XHJY20230508
• Study Type: observational
• Target: 300
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a multicenter retrospective study that collected diagnostic information of patients with pleural effusion. The overall survival (OS) time of malignant patients was followed up, defined as the time from diagnosis to death. Clinical data and residual pleural effusion specimens were collected from patients. Metabonomics was utilized to differentiate between benign and malignant pleural effusion and to evaluate the prognosis of lung cancer patients with malignant pleural effusion.

Conditions

Pleural Diseases

Outcome Measures

Primary Outcomes (1)

• Metabolomic detection of pleural effusion to distinguish between benign and malignant pleural effusion

  The concentration of metabolites in the sample of pleural effusion of benign and malignant pleural effusion patients.

  Within two weeks of detection of a pleural effusion

Secondary Outcomes (1)

• Predicting one-year survival prognosis in patients with malignant pleural effusion

  1 year

Study Arms (3)

benign pleural effusion

Patients with benign pleural effusion.

Other: Detection of pleural effusion

malignant pleural effusion patients with bad prognosis

The OS time of malignant pleural effusion patients is\<1 year.

Other: Detection of pleural effusion

malignant pleural effusion patients with good prognosis

The OS time of malignant pleural effusion patients is ≥1 year.

Other: Detection of pleural effusion

Interventions

Detection of pleural effusion OTHER

Detection of pleural effusion

benign pleural effusion; malignant pleural effusion patients with bad prognosis; malignant pleural effusion patients with good prognosis

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with pleural effusion

You may qualify if:

• Years to 80 Years; detection of pleural effusion by chest computed tomography, radiography, or ultrasonography; pathologically confirmed lung cancer in pleural effusion.

You may not qualify if:

• pleural effusion not caused by lung cancer or of unknown origin; other concurrent malignant diseases; incomplete information; lack of any follow-up data.

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

pleural effusion

MeSH Terms

Conditions

Pleural Diseases

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 8, 2023
• First Posted: June 18, 2023
• Study Start: January 1, 2016
• Primary Completion: January 1, 2023
• Study Completion: January 1, 2023
• Last Updated: June 18, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share